[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7D-UYlroCUz2fhlDqIe-0_Ow_niP6sHKofdI19pSYuI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":32,"phaseBuckets":53,"rows":60},"University of Milan",[4,6],"University of Milano Bicocca",180,false,21,16,44115,4,133,[15,18,20,22,24,26,28,30],{"name":16,"count":17},"Hepatocellular Carcinoma",7,{"name":19,"count":17},"COPD",{"name":21,"count":12},"Lung Cancer",{"name":23,"count":12},"Pneumonia",{"name":25,"count":12},"Chronic Obstructive Pulmonary Disease",{"name":27,"count":12},"Colorectal Liver Metastases",{"name":29,"count":12},"Critical Illness",{"name":31,"count":12},"Periodontitis",[33,38,43,48],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06789783","Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment","2025-09","Lithium Carbonate",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05219409","Effects of Sitagliptin in Relatives of T1D Patients","2025-12","Sitagliptin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04238221","Effect of add-on Doxofylline on Lung Function in Stable COPD","2027-12-01","Doxofylline",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06381726","Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life","2028-02-28","Up-front Chemotherapy",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,85,122,145,167,207,232,250,275,299,324,351,379,397,415,440,465,488,506,530,548,574,592,619,674,710,728,754,780,805,823,841,864,882,909,927,957,975,999,1030,1048,1066,1084,1110,1139,1168,1193,1211,1237,1263,1286,1310,1335,1359,1383,1408,1434],{"intervention":47,"totalTrials":62,"cells":63},1,{"EARLY_PHASE1":64,"PHASE1":67,"PHASE2":69,"PHASE3":71,"PHASE4":73,"NA":83},{"trials":65,"activeCount":66},[],0,{"trials":68,"activeCount":66},[],{"trials":70,"activeCount":66},[],{"trials":72,"activeCount":66},[],{"trials":74,"activeCount":62,"soonestReadout":46},[75],{"nctId":44,"briefTitle":45,"status":76,"phases":77,"primaryCompletion":46,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":82},"NOT_YET_RECRUITING",[58],"2027-12-30","2026-12-01",78,[25],[47],{"trials":84,"activeCount":66},[],{"intervention":42,"totalTrials":86,"cells":87},2,{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":118,"NA":120},{"trials":89,"activeCount":66},[],{"trials":91,"activeCount":66},[],{"trials":93,"activeCount":66},[],{"trials":95,"activeCount":62,"soonestReadout":41},[96,110],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":109},"NCT04365517","The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients","UNKNOWN",[57],"2022-03-30","2022-12-30","2021-12-29",170,[106,107,108],"Covid19","Diabetes Mellitus, Type 2","CKD",[42],{"nctId":39,"briefTitle":40,"status":76,"phases":111,"primaryCompletion":41,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},[56,57],"2027-12","2023-07",70,[116],"Type 1 Diabetes",[42],{"trials":119,"activeCount":66},[],{"trials":121,"activeCount":66},[],{"intervention":37,"totalTrials":62,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":141,"NA":143},{"trials":125,"activeCount":66},[],{"trials":127,"activeCount":66},[],{"trials":129,"activeCount":66},[],{"trials":131,"activeCount":62,"soonestReadout":36},[132],{"nctId":34,"briefTitle":35,"status":133,"phases":134,"primaryCompletion":36,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"RECRUITING",[56,57],"2026-12","2024-05-01",34,[139],"Cornelia De Lange Syndrome",[37],{"trials":142,"activeCount":66},[],{"trials":144,"activeCount":66},[],{"intervention":52,"totalTrials":62,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":157},{"trials":148,"activeCount":66},[],{"trials":150,"activeCount":66},[],{"trials":152,"activeCount":66},[],{"trials":154,"activeCount":66},[],{"trials":156,"activeCount":66},[],{"trials":158,"activeCount":62,"soonestReadout":51},[159],{"nctId":49,"briefTitle":50,"status":133,"phases":160,"primaryCompletion":51,"completion":51,"start":161,"enrollment":162,"conditions":163,"interventions":166},[59],"2024-03-07",400,[164,165],"Glioma","Glioma, Malignant",[52],{"intervention":168,"totalTrials":86,"cells":169},"Indacaterol maleate",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":205},{"trials":171,"activeCount":66},[],{"trials":173,"activeCount":66},[],{"trials":175,"activeCount":66},[],{"trials":177,"activeCount":66},[],{"trials":179,"activeCount":66},[180,195],{"nctId":181,"briefTitle":182,"status":183,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":194},"NCT01377051","Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea","COMPLETED",[58],"2011-08","2011-09","2011-05",60,[19,190,191,192,193],"Lung Diseases","Dyspnea","Hypoxemia","Tachycardia",[168],{"nctId":196,"briefTitle":197,"status":183,"phases":198,"primaryCompletion":199,"completion":199,"start":185,"enrollment":200,"conditions":201,"interventions":203},"NCT01437748","Closing Volume Interpretation and Bronchodilators Effect",[58],"2014-09",40,[202,19],"Healthy",[168,204],"Tiotropium bromide",{"trials":206,"activeCount":66},[],{"intervention":208,"totalTrials":62,"cells":209},"ceftidoren",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":230},{"trials":211,"activeCount":66},[],{"trials":213,"activeCount":66},[],{"trials":215,"activeCount":66},[],{"trials":217,"activeCount":66},[],{"trials":219,"activeCount":66},[220],{"nctId":221,"briefTitle":222,"status":183,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":200,"conditions":226,"interventions":228},"NCT01467297","Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB)",[58],"2012-06","2012-01",[227],"COPD Exacerbation",[208,229],"levofloxacin",{"trials":231,"activeCount":66},[],{"intervention":229,"totalTrials":62,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":248},{"trials":235,"activeCount":66},[],{"trials":237,"activeCount":66},[],{"trials":239,"activeCount":66},[],{"trials":241,"activeCount":66},[],{"trials":243,"activeCount":66},[244],{"nctId":221,"briefTitle":222,"status":183,"phases":245,"primaryCompletion":224,"completion":224,"start":225,"enrollment":200,"conditions":246,"interventions":247},[58],[227],[208,229],{"trials":249,"activeCount":66},[],{"intervention":251,"totalTrials":62,"cells":252},"Prasugrel",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":273},{"trials":254,"activeCount":66},[],{"trials":256,"activeCount":66},[],{"trials":258,"activeCount":66},[],{"trials":260,"activeCount":66},[],{"trials":262,"activeCount":66},[263],{"nctId":264,"briefTitle":265,"status":183,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT01305369","The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma",[58],"2011-12","2011-03",26,[271],"Chronic Asthma",[251],{"trials":274,"activeCount":66},[],{"intervention":276,"totalTrials":62,"cells":277},"tobramycin",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":297},{"trials":279,"activeCount":66},[],{"trials":281,"activeCount":66},[],{"trials":283,"activeCount":66},[],{"trials":285,"activeCount":66},[],{"trials":287,"activeCount":66},[288],{"nctId":289,"briefTitle":290,"status":183,"phases":291,"primaryCompletion":292,"completion":292,"start":225,"enrollment":293,"conditions":294,"interventions":296},"NCT01608555","Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis",[58],"2012-07",10,[295],"Cystic Fibrosis",[276],{"trials":298,"activeCount":66},[],{"intervention":300,"totalTrials":62,"cells":301},"Indacaterol Fumarate",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":322},{"trials":303,"activeCount":66},[],{"trials":305,"activeCount":66},[],{"trials":307,"activeCount":66},[],{"trials":309,"activeCount":66},[],{"trials":311,"activeCount":66},[312],{"nctId":313,"briefTitle":314,"status":183,"phases":315,"primaryCompletion":316,"completion":316,"start":317,"enrollment":200,"conditions":318,"interventions":321},"NCT01996124","Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients",[58],"2014-10","2013-11",[19,319,320],"Hyperinflation","Right Cardiac Failure",[300],{"trials":323,"activeCount":66},[],{"intervention":325,"totalTrials":62,"cells":326},"implantology",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":349},{"trials":328,"activeCount":66},[],{"trials":330,"activeCount":66},[],{"trials":332,"activeCount":66},[],{"trials":334,"activeCount":66},[],{"trials":336,"activeCount":66},[337],{"nctId":338,"briefTitle":339,"status":183,"phases":340,"primaryCompletion":341,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":348},"NCT04160689","Influence of the Implant Connection on Facial Tissues Maturation",[58],"2019-11-01","2018-11-01",104,[345,346,347],"Bone Loss","Periodontal Bone Loss","Implant Tissue Failure",[325],{"trials":350,"activeCount":66},[],{"intervention":352,"totalTrials":62,"cells":353},"hyaluronic Acid + platelet-rich plasma",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":377},{"trials":355,"activeCount":66},[],{"trials":357,"activeCount":66},[],{"trials":359,"activeCount":66},[],{"trials":361,"activeCount":66},[],{"trials":363,"activeCount":66},[364],{"nctId":365,"briefTitle":366,"status":183,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":374},"NCT03211650","Efficacy of Hyaluronic Acid and Platelet-rich Plasma Combination in Knee Osteoarthritis",[58],"2018-11-30","2021-03-27","2016-10-14",174,[373],"Knee Osteoarthritis",[352,375,376],"hyaluronic acid","platelet-rich plasma",{"trials":378,"activeCount":66},[],{"intervention":375,"totalTrials":62,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":395},{"trials":382,"activeCount":66},[],{"trials":384,"activeCount":66},[],{"trials":386,"activeCount":66},[],{"trials":388,"activeCount":66},[],{"trials":390,"activeCount":66},[391],{"nctId":365,"briefTitle":366,"status":183,"phases":392,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":393,"interventions":394},[58],[373],[352,375,376],{"trials":396,"activeCount":66},[],{"intervention":376,"totalTrials":62,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":413},{"trials":400,"activeCount":66},[],{"trials":402,"activeCount":66},[],{"trials":404,"activeCount":66},[],{"trials":406,"activeCount":66},[],{"trials":408,"activeCount":66},[409],{"nctId":365,"briefTitle":366,"status":183,"phases":410,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":411,"interventions":412},[58],[373],[352,375,376],{"trials":414,"activeCount":66},[],{"intervention":416,"totalTrials":62,"cells":417},"Probiotic Vivomixx",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":426,"NA":438},{"trials":419,"activeCount":66},[],{"trials":421,"activeCount":66},[],{"trials":423,"activeCount":66},[],{"trials":425,"activeCount":66},[],{"trials":427,"activeCount":66},[428],{"nctId":429,"briefTitle":430,"status":99,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":437},"NCT04160767","Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) in a Cohoort of Celiac Patients",[58],"2021-07","2019-01-30",90,[436],"Celiac Disease",[416],{"trials":439,"activeCount":66},[],{"intervention":441,"totalTrials":62,"cells":442},"Docosahexaenoic Acid Supplementation",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":463},{"trials":444,"activeCount":66},[],{"trials":446,"activeCount":66},[],{"trials":448,"activeCount":66},[],{"trials":450,"activeCount":66},[],{"trials":452,"activeCount":66},[453],{"nctId":454,"briefTitle":455,"status":99,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":462},"NCT04151758","Effect of Docosahexaenoic Acid Supplementation on Microbiome in Obese ChiLdrEn.",[58],"2021-05-30","2019-01-07",30,[461],"Childhood Obesity",[441],{"trials":464,"activeCount":66},[],{"intervention":466,"totalTrials":62,"cells":467},"Vitamin D3",{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":476,"NA":486},{"trials":469,"activeCount":66},[],{"trials":471,"activeCount":66},[],{"trials":473,"activeCount":66},[],{"trials":475,"activeCount":66},[],{"trials":477,"activeCount":66},[478],{"nctId":479,"briefTitle":480,"status":99,"phases":481,"primaryCompletion":482,"completion":482,"start":458,"enrollment":459,"conditions":483,"interventions":484},"NCT04151823","Effect of POSTbiotics Supplementation on Microbiome in OBese Children: the POST-OB Study",[58],"2021-01-07",[461],[466,485],"Immunofos",{"trials":487,"activeCount":66},[],{"intervention":485,"totalTrials":62,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":504},{"trials":491,"activeCount":66},[],{"trials":493,"activeCount":66},[],{"trials":495,"activeCount":66},[],{"trials":497,"activeCount":66},[],{"trials":499,"activeCount":66},[500],{"nctId":479,"briefTitle":480,"status":99,"phases":501,"primaryCompletion":482,"completion":482,"start":458,"enrollment":459,"conditions":502,"interventions":503},[58],[461],[466,485],{"trials":505,"activeCount":66},[],{"intervention":507,"totalTrials":62,"cells":508},"Aclidinium Bromide",{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":528},{"trials":510,"activeCount":66},[],{"trials":512,"activeCount":66},[],{"trials":514,"activeCount":66},[],{"trials":516,"activeCount":66},[],{"trials":518,"activeCount":66},[519],{"nctId":520,"briefTitle":521,"status":183,"phases":522,"primaryCompletion":199,"completion":316,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT02181023","Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients",[58],"2014-06",37,[25],[507,527],"Glycopyrronium Bromide",{"trials":529,"activeCount":66},[],{"intervention":527,"totalTrials":62,"cells":531},{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":538,"PHASE4":540,"NA":546},{"trials":533,"activeCount":66},[],{"trials":535,"activeCount":66},[],{"trials":537,"activeCount":66},[],{"trials":539,"activeCount":66},[],{"trials":541,"activeCount":66},[542],{"nctId":520,"briefTitle":521,"status":183,"phases":543,"primaryCompletion":199,"completion":316,"start":523,"enrollment":524,"conditions":544,"interventions":545},[58],[25],[507,527],{"trials":547,"activeCount":66},[],{"intervention":549,"totalTrials":62,"cells":550},"Formoterol Fumarate",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":572},{"trials":552,"activeCount":66},[],{"trials":554,"activeCount":66},[],{"trials":556,"activeCount":66},[],{"trials":558,"activeCount":66},[],{"trials":560,"activeCount":66},[561],{"nctId":562,"briefTitle":563,"status":183,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT01853787","Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study",[58],"2015-06","2014-07",49,[569],"Chronic Obstructive Pulmonary Disease (COPD)",[549,571],"Salmeterol",{"trials":573,"activeCount":66},[],{"intervention":204,"totalTrials":62,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":590},{"trials":577,"activeCount":66},[],{"trials":579,"activeCount":66},[],{"trials":581,"activeCount":66},[],{"trials":583,"activeCount":66},[],{"trials":585,"activeCount":66},[586],{"nctId":196,"briefTitle":197,"status":183,"phases":587,"primaryCompletion":199,"completion":199,"start":185,"enrollment":200,"conditions":588,"interventions":589},[58],[202,19],[168,204],{"trials":591,"activeCount":66},[],{"intervention":593,"totalTrials":62,"cells":594},"Oral melatonin 3mg BID",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":617},{"trials":596,"activeCount":66},[],{"trials":598,"activeCount":66},[],{"trials":600,"activeCount":66},[],{"trials":602,"activeCount":66},[],{"trials":604,"activeCount":66},[605],{"nctId":606,"briefTitle":607,"status":183,"phases":608,"primaryCompletion":609,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":616},"NCT00470821","Oral Melatonin in Critically Ill High-risk Patients",[58],"2010-04","2010-05","2007-05",96,[614,615],"Critically Ill Patients","Mechanically Ventilated Patients",[593],{"trials":618,"activeCount":66},[],{"intervention":620,"totalTrials":12,"cells":621},"Sildenafil",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":639,"PHASE4":670,"NA":672},{"trials":623,"activeCount":66},[],{"trials":625,"activeCount":66},[],{"trials":627,"activeCount":66},[628],{"nctId":629,"briefTitle":630,"status":183,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"NCT01185925","Exercise Oscillatory Breathing and Sildenafil in Heart Failure",[56],"2009-12","2010-06","2008-04",32,[637],"Heart Failure",[620],{"trials":640,"activeCount":66},[641,650,659],{"nctId":642,"briefTitle":643,"status":183,"phases":644,"completion":645,"start":646,"enrollment":200,"conditions":647,"interventions":648},"NCT00407446","PDE5-Inhibition With Sildenafil in Chronic Heart Failure",[57],"2005-02","2004-01",[637],[649],"sildenafil",{"nctId":651,"briefTitle":652,"status":183,"phases":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT00975494","Chronic Sildenafil Treatment in Heart Failure",[57],"2008-12","2005-04",50,[637],[620],{"nctId":660,"briefTitle":661,"status":183,"phases":662,"primaryCompletion":663,"completion":632,"start":664,"enrollment":665,"conditions":666,"interventions":669},"NCT01156636","Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure",[56,57],"2009-09","2006-01",44,[667,668],"Pulmonary Hypertension","Diastolic Heart Failure",[620],{"trials":671,"activeCount":66},[],{"trials":673,"activeCount":66},[],{"intervention":675,"totalTrials":86,"cells":676},"Chlorhexidine mouthwash",{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":706,"NA":708},{"trials":678,"activeCount":66},[],{"trials":680,"activeCount":66},[],{"trials":682,"activeCount":66},[],{"trials":684,"activeCount":66},[685,697],{"nctId":686,"briefTitle":687,"status":99,"phases":688,"primaryCompletion":689,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":695},"NCT04438434","Evaluation of Hydrogen Peroxide and Hyaluronic Acid (BMG0703) in the Healing of Post-extraction Sites",[57],"2020-07","2020-06",57,[693,694],"Impacted Third Molar Tooth","Healing Surgical Wounds",[696,675],"Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid",{"nctId":698,"briefTitle":699,"status":99,"phases":700,"primaryCompletion":689,"completion":689,"start":690,"enrollment":656,"conditions":701,"interventions":704},"NCT04438421","Efficacy of Hyaluronic-acid and Hydrogen-Peroxide Mouthwash in Gingivitis Treatment",[57],[702,703],"Gingivitis","Bleeding Gum",[705,675],"Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid",{"trials":707,"activeCount":66},[],{"trials":709,"activeCount":66},[],{"intervention":696,"totalTrials":62,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":724,"NA":726},{"trials":713,"activeCount":66},[],{"trials":715,"activeCount":66},[],{"trials":717,"activeCount":66},[],{"trials":719,"activeCount":66},[720],{"nctId":686,"briefTitle":687,"status":99,"phases":721,"primaryCompletion":689,"completion":689,"start":690,"enrollment":691,"conditions":722,"interventions":723},[57],[693,694],[696,675],{"trials":725,"activeCount":66},[],{"trials":727,"activeCount":66},[],{"intervention":729,"totalTrials":62,"cells":730},"intravenous and oral N-acetylcysteine",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":750,"NA":752},{"trials":732,"activeCount":66},[],{"trials":734,"activeCount":66},[],{"trials":736,"activeCount":66},[],{"trials":738,"activeCount":66},[739],{"nctId":740,"briefTitle":741,"status":183,"phases":742,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":749},"NCT00237614","Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction",[56,57],"2005-05","2003-02",300,[747,748],"Contrast-Induced Nephropathy","Acute Myocardial Infarction",[729],{"trials":751,"activeCount":66},[],{"trials":753,"activeCount":66},[],{"intervention":755,"totalTrials":62,"cells":756},"Quadrivalent Human Papillomavirus",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":776,"NA":778},{"trials":758,"activeCount":66},[],{"trials":760,"activeCount":66},[],{"trials":762,"activeCount":66},[],{"trials":764,"activeCount":66},[765],{"nctId":766,"briefTitle":767,"status":99,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":775},"NCT01512784","Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults",[57],"2013-07","2011-10",100,[773,774],"HPV","HIV",[755,755],{"trials":777,"activeCount":66},[],{"trials":779,"activeCount":66},[],{"intervention":781,"totalTrials":62,"cells":782},"Bimatoprost",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":801,"NA":803},{"trials":784,"activeCount":66},[],{"trials":786,"activeCount":66},[],{"trials":788,"activeCount":66},[],{"trials":790,"activeCount":66},[791],{"nctId":792,"briefTitle":793,"status":183,"phases":794,"primaryCompletion":795,"enrollment":796,"conditions":797,"interventions":799},"NCT02154217","Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures",[57],"2004-12",200,[798],"Glaucoma",[781,800],"Latanoprost\u002FTimolol",{"trials":802,"activeCount":66},[],{"trials":804,"activeCount":66},[],{"intervention":800,"totalTrials":62,"cells":806},{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":819,"NA":821},{"trials":808,"activeCount":66},[],{"trials":810,"activeCount":66},[],{"trials":812,"activeCount":66},[],{"trials":814,"activeCount":66},[815],{"nctId":792,"briefTitle":793,"status":183,"phases":816,"primaryCompletion":795,"enrollment":796,"conditions":817,"interventions":818},[57],[798],[781,800],{"trials":820,"activeCount":66},[],{"trials":822,"activeCount":66},[],{"intervention":705,"totalTrials":62,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":837,"NA":839},{"trials":826,"activeCount":66},[],{"trials":828,"activeCount":66},[],{"trials":830,"activeCount":66},[],{"trials":832,"activeCount":66},[833],{"nctId":698,"briefTitle":699,"status":99,"phases":834,"primaryCompletion":689,"completion":689,"start":690,"enrollment":656,"conditions":835,"interventions":836},[57],[702,703],[705,675],{"trials":838,"activeCount":66},[],{"trials":840,"activeCount":66},[],{"intervention":842,"totalTrials":62,"cells":843},"Hydrogen Peroxide and Hyaluronic acid filming formulation",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":850,"PHASE4":860,"NA":862},{"trials":845,"activeCount":66},[],{"trials":847,"activeCount":66},[],{"trials":849,"activeCount":66},[],{"trials":851,"activeCount":66},[852],{"nctId":853,"briefTitle":854,"status":99,"phases":855,"primaryCompletion":689,"completion":689,"start":690,"enrollment":656,"conditions":856,"interventions":858},"NCT04446533","Effect of a Hydrogen-Peroxide and Hyaluronic-Acid Mouthwash (BMG0703) in the Treatment of Periodontitis",[57],[31,703,857],"Pocket, Periodontal",[842,859],"Chlorhexidine 0.2%",{"trials":861,"activeCount":66},[],{"trials":863,"activeCount":66},[],{"intervention":859,"totalTrials":62,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":878,"NA":880},{"trials":867,"activeCount":66},[],{"trials":869,"activeCount":66},[],{"trials":871,"activeCount":66},[],{"trials":873,"activeCount":66},[874],{"nctId":853,"briefTitle":854,"status":99,"phases":875,"primaryCompletion":689,"completion":689,"start":690,"enrollment":656,"conditions":876,"interventions":877},[57],[31,703,857],[842,859],{"trials":879,"activeCount":66},[],{"trials":881,"activeCount":66},[],{"intervention":883,"totalTrials":62,"cells":884},"Zinc L-Carnosine",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":905,"NA":907},{"trials":886,"activeCount":66},[],{"trials":888,"activeCount":66},[],{"trials":890,"activeCount":66},[],{"trials":892,"activeCount":66},[893],{"nctId":894,"briefTitle":895,"status":99,"phases":896,"primaryCompletion":897,"completion":898,"start":690,"enrollment":899,"conditions":900,"interventions":903},"NCT04430998","Efficacy of Zinc L-Carnosine Mouth Rinse",[57],"2020-06-22","2020-06-30",75,[901,902],"Periodontal Index","Pain",[883,904],"Chlorhexidine",{"trials":906,"activeCount":66},[],{"trials":908,"activeCount":66},[],{"intervention":904,"totalTrials":62,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":923,"NA":925},{"trials":912,"activeCount":66},[],{"trials":914,"activeCount":66},[],{"trials":916,"activeCount":66},[],{"trials":918,"activeCount":66},[919],{"nctId":894,"briefTitle":895,"status":99,"phases":920,"primaryCompletion":897,"completion":898,"start":690,"enrollment":899,"conditions":921,"interventions":922},[57],[901,902],[883,904],{"trials":924,"activeCount":66},[],{"trials":926,"activeCount":66},[],{"intervention":928,"totalTrials":62,"cells":929},"azithromycin and fluticasone",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":931,"activeCount":66},[],{"trials":933,"activeCount":66},[],{"trials":935,"activeCount":66},[936],{"nctId":937,"briefTitle":938,"status":939,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":949},"NCT00524095","Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis","TERMINATED",[56],"2008-07","2009-02","2006-09",210,[946,947,948],"Bronchiectasis","Pulmonary Disease","Chronic Bronchitis",[928,950],"fluticasone and azithromycin",{"trials":952,"activeCount":66},[],{"trials":954,"activeCount":66},[],{"trials":956,"activeCount":66},[],{"intervention":950,"totalTrials":62,"cells":958},{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":960,"activeCount":66},[],{"trials":962,"activeCount":66},[],{"trials":964,"activeCount":66},[965],{"nctId":937,"briefTitle":938,"status":939,"phases":966,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":967,"interventions":968},[56],[946,947,948],[928,950],{"trials":970,"activeCount":66},[],{"trials":972,"activeCount":66},[],{"trials":974,"activeCount":66},[],{"intervention":976,"totalTrials":62,"cells":977},"azithromycin",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":979,"activeCount":66},[],{"trials":981,"activeCount":66},[],{"trials":983,"activeCount":66},[984],{"nctId":985,"briefTitle":986,"status":939,"phases":987,"completion":988,"start":989,"enrollment":459,"conditions":990,"interventions":992},"NCT00323986","Azithromycin Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and Tracheostomy",[56],"2006-04","2004-10",[19,991],"Tracheostomy",[976],{"trials":994,"activeCount":66},[],{"trials":996,"activeCount":66},[],{"trials":998,"activeCount":66},[],{"intervention":1000,"totalTrials":62,"cells":1001},"Tirofiban",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1003,"activeCount":66},[],{"trials":1005,"activeCount":66},[],{"trials":1007,"activeCount":66},[1008],{"nctId":1009,"briefTitle":1010,"status":183,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1020},"NCT04368377","Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19",[56],"2020-04-23","2020-04-06",5,[1016,1017,1018,1019],"Pneumonia, Viral","Corona Virus Infection","Respiratory Failure","Embolism and Thrombosis",[1000,1021,1022,1023],"Clopidogrel","Acetylsalicylic acid","Fondaparinux",{"trials":1025,"activeCount":66},[],{"trials":1027,"activeCount":66},[],{"trials":1029,"activeCount":66},[],{"intervention":1021,"totalTrials":62,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1033,"activeCount":66},[],{"trials":1035,"activeCount":66},[],{"trials":1037,"activeCount":66},[1038],{"nctId":1009,"briefTitle":1010,"status":183,"phases":1039,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1040,"interventions":1041},[56],[1016,1017,1018,1019],[1000,1021,1022,1023],{"trials":1043,"activeCount":66},[],{"trials":1045,"activeCount":66},[],{"trials":1047,"activeCount":66},[],{"intervention":1022,"totalTrials":62,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":66},[],{"trials":1053,"activeCount":66},[],{"trials":1055,"activeCount":66},[1056],{"nctId":1009,"briefTitle":1010,"status":183,"phases":1057,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1058,"interventions":1059},[56],[1016,1017,1018,1019],[1000,1021,1022,1023],{"trials":1061,"activeCount":66},[],{"trials":1063,"activeCount":66},[],{"trials":1065,"activeCount":66},[],{"intervention":1023,"totalTrials":62,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1069,"activeCount":66},[],{"trials":1071,"activeCount":66},[],{"trials":1073,"activeCount":66},[1074],{"nctId":1009,"briefTitle":1010,"status":183,"phases":1075,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1076,"interventions":1077},[56],[1016,1017,1018,1019],[1000,1021,1022,1023],{"trials":1079,"activeCount":66},[],{"trials":1081,"activeCount":66},[],{"trials":1083,"activeCount":66},[],{"intervention":1085,"totalTrials":62,"cells":1086},"oral cholecalciferol 1000000 UI",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1088,"activeCount":66},[],{"trials":1090,"activeCount":66},[],{"trials":1092,"activeCount":66},[1093],{"nctId":1094,"briefTitle":1095,"status":183,"phases":1096,"primaryCompletion":292,"completion":292,"start":1097,"enrollment":656,"conditions":1098,"interventions":1103},"NCT01656070","Vitamin D Supplementation in HIV-infected Youth",[56],"2011-04",[1099,1100,1101,1102],"HIV Disease","Vitamin D Deficiency","Hypovitaminosis D","Hyperparathyroidism",[1085],{"trials":1105,"activeCount":66},[],{"trials":1107,"activeCount":66},[],{"trials":1109,"activeCount":66},[],{"intervention":571,"totalTrials":86,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1126},{"trials":1113,"activeCount":66},[],{"trials":1115,"activeCount":66},[],{"trials":1117,"activeCount":66},[],{"trials":1119,"activeCount":66},[],{"trials":1121,"activeCount":66},[1122],{"nctId":562,"briefTitle":563,"status":183,"phases":1123,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":1124,"interventions":1125},[58],[569],[549,571],{"trials":1127,"activeCount":66},[1128],{"nctId":1129,"briefTitle":1130,"status":183,"phases":1131,"primaryCompletion":1132,"completion":1133,"start":654,"enrollment":1134,"conditions":1135,"interventions":1138},"NCT01271556","Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients",[59],"2009-03","2009-07",20,[1136,25,1137,571],"Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients","Bronchodilator Agents",[571],{"intervention":1140,"totalTrials":62,"cells":1141},"Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1143,"activeCount":66},[],{"trials":1145,"activeCount":66},[],{"trials":1147,"activeCount":66},[],{"trials":1149,"activeCount":66},[],{"trials":1151,"activeCount":66},[],{"trials":1153,"activeCount":66},[1154],{"nctId":1155,"briefTitle":1156,"status":99,"phases":1157,"primaryCompletion":1158,"completion":1159,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1167},"NCT04272359","Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus",[],"2021-10-06","2021-12-31","2019-05-06",138,[1163,1164,1165,1166],"T2DM (Type 2 Diabetes Mellitus)","Diet, Healthy","Renal Function Disorder","Albuminuria",[1140],{"intervention":1169,"totalTrials":62,"cells":1170},"Chlorhexidine gluconate with ADS",{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1172,"activeCount":66},[],{"trials":1174,"activeCount":66},[],{"trials":1176,"activeCount":66},[],{"trials":1178,"activeCount":66},[],{"trials":1180,"activeCount":66},[],{"trials":1182,"activeCount":66},[1183],{"nctId":1184,"briefTitle":1185,"status":183,"phases":1186,"primaryCompletion":1187,"completion":292,"start":267,"enrollment":1188,"conditions":1189,"interventions":1191},"NCT02709824","Anti-staining Efficacy of Anti-Discoloration System (ADS) Added to Chlorhexidine (CHX)",[59],"2012-02",22,[1190],"Adverse Effect",[1169,1192],"Chlorhexidine gluconate without ADS",{"intervention":1192,"totalTrials":62,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1196,"activeCount":66},[],{"trials":1198,"activeCount":66},[],{"trials":1200,"activeCount":66},[],{"trials":1202,"activeCount":66},[],{"trials":1204,"activeCount":66},[],{"trials":1206,"activeCount":66},[1207],{"nctId":1184,"briefTitle":1185,"status":183,"phases":1208,"primaryCompletion":1187,"completion":292,"start":267,"enrollment":1188,"conditions":1209,"interventions":1210},[59],[1190],[1169,1192],{"intervention":1212,"totalTrials":62,"cells":1213},"Evicel",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1215,"activeCount":66},[],{"trials":1217,"activeCount":66},[],{"trials":1219,"activeCount":66},[],{"trials":1221,"activeCount":66},[],{"trials":1223,"activeCount":66},[],{"trials":1225,"activeCount":66},[1226],{"nctId":1227,"briefTitle":1228,"status":183,"phases":1229,"primaryCompletion":1230,"completion":224,"start":268,"enrollment":1231,"conditions":1232,"interventions":1236},"NCT01816282","The Use of Fibrin Sealant to Reduce Bleeding After Total Knee Replacement",[59],"2012-04",62,[1233,1234,1235],"Total Knee Replacement","Primary Knee Arthroplasty","Osteoarthritis of the Knee",[1212],{"intervention":1238,"totalTrials":62,"cells":1239},"Test - xHyA",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1241,"activeCount":66},[],{"trials":1243,"activeCount":66},[],{"trials":1245,"activeCount":66},[],{"trials":1247,"activeCount":66},[],{"trials":1249,"activeCount":66},[],{"trials":1251,"activeCount":66},[1252],{"nctId":1253,"briefTitle":1254,"status":183,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1134,"conditions":1259,"interventions":1262},"NCT07458685","Influence of Hyaluronic Acid in the Healing of Palatal Donor Sites During Free Gingival Graft Procedures",[59],"2025-07-24","2025-10-02","2022-09-05",[1260,1261],"Palatal Donor Site Wound Healing","Palatal Wound",[1238],{"intervention":1264,"totalTrials":62,"cells":1265},"recombinant human somatotropin",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1267,"activeCount":66},[],{"trials":1269,"activeCount":66},[],{"trials":1271,"activeCount":66},[],{"trials":1273,"activeCount":66},[],{"trials":1275,"activeCount":66},[],{"trials":1277,"activeCount":66},[1278],{"nctId":1279,"briefTitle":1280,"status":99,"phases":1281,"conditions":1282,"interventions":1285},"NCT00497484","Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)",[59],[1283,1284],"Pseudohypoparathyroidism","Growth Hormone Deficiency, Dwarfism",[1264],{"intervention":1287,"totalTrials":62,"cells":1288},"Retrospective case-control analysis",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1290,"activeCount":66},[],{"trials":1292,"activeCount":66},[],{"trials":1294,"activeCount":66},[],{"trials":1296,"activeCount":66},[],{"trials":1298,"activeCount":66},[],{"trials":1300,"activeCount":66},[1301],{"nctId":1302,"briefTitle":1303,"status":183,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1309},"NCT04382794","Sitagliptin Treatment in Diabetic COVID-19 Positive Patients",[],"2020-06-15","2020-05-14",338,[106],[1287],{"intervention":1311,"totalTrials":62,"cells":1312},"Dapagliflozin 10mg",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1314,"activeCount":66},[],{"trials":1316,"activeCount":66},[],{"trials":1318,"activeCount":66},[],{"trials":1320,"activeCount":66},[],{"trials":1322,"activeCount":66},[],{"trials":1324,"activeCount":66},[1325],{"nctId":1326,"briefTitle":1327,"status":99,"phases":1328,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1331,"conditions":1332,"interventions":1334},"NCT05418946","The Effects of Dapagliflozin in Normal Clinical Practice in T2D",[],"2022-12","2022-06",1400,[1333],"Type 2 Diabetes",[1311],{"intervention":1336,"totalTrials":62,"cells":1337},"usual drug therapy",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1339,"activeCount":66},[],{"trials":1341,"activeCount":66},[],{"trials":1343,"activeCount":66},[],{"trials":1345,"activeCount":66},[],{"trials":1347,"activeCount":66},[],{"trials":1349,"activeCount":66},[1350],{"nctId":1351,"briefTitle":1352,"status":183,"phases":1353,"primaryCompletion":186,"completion":1354,"start":268,"enrollment":656,"conditions":1355,"interventions":1358},"NCT02828072","Sudarshan Kriya Yoga and Cardiac Autonomic Control in Patients With Anxiety-Depression Disorders",[59],"2012-03",[1356,1357],"Anxiety","Depression",[1336],{"intervention":1360,"totalTrials":62,"cells":1361},"fitostimoline vaginal pessaries",{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1363,"activeCount":66},[],{"trials":1365,"activeCount":66},[],{"trials":1367,"activeCount":66},[],{"trials":1369,"activeCount":66},[],{"trials":1371,"activeCount":66},[],{"trials":1373,"activeCount":66},[1374],{"nctId":1375,"briefTitle":1376,"status":99,"phases":1377,"primaryCompletion":1378,"completion":1379,"start":1378,"enrollment":188,"conditions":1380,"interventions":1382},"NCT04612881","Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.",[],"2020-10-18","2021-09-18",[1381],"Vaginal Bleeding",[1360],{"intervention":1384,"totalTrials":62,"cells":1385},"SGLT2 inhibitor",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1387,"activeCount":66},[],{"trials":1389,"activeCount":66},[],{"trials":1391,"activeCount":66},[],{"trials":1393,"activeCount":66},[],{"trials":1395,"activeCount":66},[],{"trials":1397,"activeCount":66},[1398],{"nctId":1399,"briefTitle":1400,"status":99,"phases":1401,"primaryCompletion":1329,"completion":1402,"start":1403,"enrollment":1404,"conditions":1405,"interventions":1407},"NCT05477017","Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients",[],"2023-03","2022-09",800,[1406],"Type2Diabetes",[1384],{"intervention":1409,"totalTrials":62,"cells":1410},"Doxycyclin",{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1412,"activeCount":66},[],{"trials":1414,"activeCount":66},[],{"trials":1416,"activeCount":66},[],{"trials":1418,"activeCount":66},[],{"trials":1420,"activeCount":66},[],{"trials":1422,"activeCount":66},[1423],{"nctId":1424,"briefTitle":1425,"status":183,"phases":1426,"primaryCompletion":136,"completion":136,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1433},"NCT06520007","Comparison Between Continuous and Pulsed Oral Doxycycline Treatment Protocols for Refractory Meibomian Gland Dysfunction",[],"2023-03-01",65,[1430,1431,1432],"Meibomian Gland Dysfunction","Blepharitis","Doxycycline Adverse Reaction",[1409],{"intervention":1435,"totalTrials":62,"cells":1436},"Arginine",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1438,"activeCount":66},[],{"trials":1440,"activeCount":66},[],{"trials":1442,"activeCount":66},[],{"trials":1444,"activeCount":66},[],{"trials":1446,"activeCount":66},[],{"trials":1448,"activeCount":66},[1449],{"nctId":1450,"briefTitle":1451,"status":183,"phases":1452,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1457,"interventions":1459},"NCT05412160","Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD",[59],"2024-12-01","2024-12-30","2023-01-18",153,[19,191,1458],"Argininemia",[1435]]